In todays fast-paced world, it is easy to miss out on important information, especially if you are trying to keep up with a lot of different sources. That is where the daily digest comes in – it is a tool that compiles all the posts created on the previous day, providing you with a convenient […]
Continue Reading
Seagen, the biotech company Pfizer is buying for $43 billion, is considered a pioneer in the class of cancer drugs called antibody drug conjugates. But the first ADC to reach the market wasn’t a…
Continue Reading
Sengkang General Hospital in Singapore is turning into a centre of excellence for AI-assisted colonoscopy with support from Medtronic International.The two organisations have signed a memorandum of understanding to promote AI-assisted colonoscopy for colorectal cancer…
Continue Reading
The latest Digital Health news industry round-up includes an award of £1.4m for Mendelian to further develop its AI solutions, a pilot for a state-of-the-art prehabilitation programme at James Paget University Hospitals and the…
Continue Reading
By Sara Heath March 02, 2023 – A new study out of Tulane University confirms what many may have been able to guess about patient access to care: paid sick leave policies…
Continue Reading
The hot topic around the virtual water cooler this week was the National Labor Relations Board (NLRB) decision this week that employers can no longer use two specific strategies to silence laid-off employees. Employers…
Continue Reading
What You Should Know:– Lucem Health™ today announced the availability of its new early AI-driven disease detection solutions, Lucem Health Reveal that leverages existing EHR data to identify patients who may be at a…
Continue Reading
G1 Therapeutics’ approach to cancer does not kill tumors. Instead, the biotech’s drug, trilaciclib, protects bone marrow from the damaging effects of chemotherapy, reducing the duration and severity of the problems that can limit the use of this cancer treatment. Since trilaciclib’s initial approval insmall cell lung cancer, G1 has pursued more clinical trials that could support expanding the drug to other cancers. Colorectal cancer will no longer be one of them.
On Monday, G1 reported preliminary data showing that the placebo group outperformed the trilaciclib arm in helping patients live longer. G1 said it has decided to stop the colorectal cancer…
SA Health, together with the Commission on Excellence and Innovation in Health, will start collecting and analysing patient-reported measures across South Australia through its new programme.The Patient Reported Measures (PRM) programme will support clinical services to deliver “high-quality, patient-centred, and value-driven care” by encouraging patients to report on health outcomes and experiences.
SA Health and CIEH have chosen digital health company The Clinician via an open tender process to help implement the programme. They will leverage the latter’s ZEDOC platform, which will be integrated with SA Health’s IT systems to automate the distribution, collection, and analysis of patient-reported outcomes and experience measures.
WHY IT…
Subscribe for your weekly fix of health tech stories, wherever you get your news: Apple, Spotify, or Twitter.Vijay Kedar, CEO & Co-Founder, Tomorrow HealthIn this episode, I sat down with Vijay Kedar, CEO and Co-Founder, of…
Continue Reading
